crb-701
mAbexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2024 (NCT06265727)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Nectin-4INHIBITOR
NECTIN4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06265727 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2024 | Corbus Pharmaceuticals Inc., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Imperial College London, University of Chicago |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corbus Pharmaceuticals Inc. | For profit | 1 | 1 | 1 | 2024 |
| CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | For profit | 1 | 0 | 1 | 2024 |
| Imperial College London | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1